West Pharmaceutical Services, Inc. achieved an impressive first-quarter 2022 with adjusted earnings per share (EPS) of $2.30, exceeding expectations by 5.5% and reflecting a 12.2% year-over-year increase. While revenues reached $720 million—up 7.4% from the previous year—they slightly fell short of forecasts, attributed in part to foreign currency fluctuations. The company is confident in its full-year outlook, raising projections for both net sales and adjusted EPS, and has noted significant organic sales growth of 11% amidst ongoing market challenges.
“West Pharmaceutical Services, Inc. · reported · first-quarter 2022 adjusted earnings per share (EPS) · $2.30”
“West Pharmaceutical Services, Inc. · beat · the Zacks Consensus Estimate of adjusted EPS · $2.18”
“West Pharmaceutical Services, Inc. · experienced · year-over-year EPS improvement · 12.2%”
“West Pharmaceutical Services, Inc. · reported · revenues · $720 million”
“West Pharmaceutical Services, Inc. · increased revenues · year-over-year · 7.4%”
“West Pharmaceutical Services, Inc. · missed · the Zacks Consensus Estimate for revenues · 0.7%”
“West Pharmaceutical Services, Inc. · experienced · organic sales growth · 11%”
“West Pharmaceutical Services, Inc. · reported · gross profit · $284.6 million”
“West Pharmaceutical Services, Inc. · operating income was · $189.7 million”
“West Pharmaceutical Services, Inc. · has cash and cash equivalents of · $667.7 million”
“West Pharmaceutical Services, Inc. · exited the first quarter with · operating cash flow · $151.2 million”
“West Pharmaceutical Services, Inc. · projected · full-year 2022 net sales outlook · between $3.05 billion and $3.08 billion”